From: Targeting macrophages: a novel treatment strategy in solid tumors
Code | Inhibitor type | Conditions | Monotherapy or Combination | Number of patients recruited | Phases stage | Clinical trial NO |
---|---|---|---|---|---|---|
CC-95251 | Human | Advanced solid and hematologic cancers | Monotherapy, or Combination | 230 participants | Phase I | NCT03783403 |
BI 765,063 (OSE-172) | Humanized IgG4 | Solid tumors | Combination | 18 participants | Phase I | NCT04653142 |
 |  | Solid tumor, adult | Combination | 116 participants | Phase I | NCT03990233 |
 |  | HNSCC melanoma NSCLC | Combination | 22 participants | Phase I | NCT05068102 |
 |  | HNSCC | Combination | 150 participants | Phase I | NCT05249426 |
Evorpacept (ALX148) | mutated SIRPα-Fc IgG1 | HNSCC | Combination | 168 participants | Phase II | NCT04675333 |
 |  | HNSCC | Combination | 183 participants | Phase II | NCT04675294 |
 |  | HER2 + gastric cancer | Combination | 450 participants | Phase II/III | NCT05002127 |
 |  | Metastatic cancer; solid tumor; advanced cancer; NHL | Combination | 174 participants | Phase I | NCT03013218 |
 |  | Microsatellite stable metastatic colorectal cancer | Combination | 80 participants | Phase II | NCT05167409 |
 |  | HER2-expressing cancers | Combination | 93 participants | Phase I/II | NCT05027139 |
TTI-621 | SIRPα-Fc IgG1 | R/R solid tumors and mycosis fungoides | Monotherapy,or combination | 174 participants | Phase I | NCT02890368 |
 |  | Hematologic malignancies solid tumor | Monotherapy, or combination | 250 participants | Phase I | NCT02663518 |
 |  | Leiomyosarcoma | Combination | 80 participants | Phase I/II | NCT04996004 |
TTI-622 | SIRPα-Fc IgG4 | Platinum-resistant ovarian cancer | Combination | 50 participants | Phase I/II | NCT05261490 |